Alberto Ortiz A.
- Country
- Spain
- Department
- Nefrología
Research Overview
- Effect of Survodutide on Albuminuria in Patients with Chronic Kidney Disease
- Phase I/IIa Multicenter Study of TranspoCART19 CD19 CAR‑T Cell Therapy in Patients with Refractory Lupus Nephritis: Safety and Preliminary Efficacy
- Phase III Randomized, Double‑Blind, Parallel‑Group Study of Elecoglipron Added to Dapagliflozin in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function
Data & Insights
Has run more than one trial at 271 of 873 partner sites.
Specializations
Chronic Kidney Disease Management
The investigator specializes in treating complex chronic kidney disease (CKD) conditions, with particular emphasis on patients with comorbid conditions such as type 2 diabetes and hypertension. Their research explores innovative therapeutic approaches using combinations of medications for improved patient outcomes.
- CKD progression monitoring
- Diabetic kidney disease treatment
- Cardiovascular complications in CKD
Glomerular Diseases
The investigator focuses on treating various forms of glomerular disorders, particularly IgA Nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Their work involves evaluating novel therapeutic agents for managing proteinuria and preserving renal function.
- IgA Nephropathy treatment innovations
- Proteinuria management
- Glomerular disease progression
Acute Kidney Injury Prevention
The investigator has developed expertise in preventing and managing cardiac surgery-associated acute kidney injury. Their work extends to exploring protective measures for patients undergoing cardiac procedures who are at risk of kidney complications.
- Perioperative kidney protection
- Post-surgical kidney care
- Major adverse kidney events prevention
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.